Redmile Group, LLC Annexon, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q2 2024

A detailed history of Redmile Group, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 6,427,462 shares of ANNX stock, worth $37 Million. This represents 2.05% of its overall portfolio holdings.

Number of Shares

6,427,462

Previous 5,503,190 16.8%

Holding current value

$37 Million

Previous $39.5 Million 20.18%

% of portfolio

2.05%

Previous 1.56%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $4 Million - $6.28 Million	924,272 Added 16.8%	6,427,462 $31.5 Million
Q4 2023 Feb 14, 2024	BUY	$1.63 - $4.63 $3.26 Million - $9.26 Million	2,000,000 Added 57.09%	5,503,190 $25 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $4.06 $633,576 - $1.22 Million	300,273 Added 9.37%	3,503,190 $13.2 Million
Q1 2022 May 16, 2022	SELL	$2.73 - $11.94 $70,980 - $310,440	-26,000 Reduced 0.81%	3,202,917 $8.74 Million
Q4 2021 Feb 14, 2022	SELL	$11.49 - $22.0 $1.38 Million - $2.65 Million	-120,268 Reduced 3.59%	3,228,917 $37.1 Million
Q3 2021 Nov 15, 2021	SELL	$16.35 - $23.4 $1.24 Million - $1.77 Million	-75,853 Reduced 2.21%	3,349,185 $62.3 Million
Q2 2021 Aug 16, 2021	SELL	$17.81 - $27.48 $601,835 - $928,604	-33,792 Reduced 0.98%	3,425,038 $77.1 Million
Q1 2021 May 17, 2021	BUY	$22.0 - $35.01 $237,600 - $378,108	10,800 Added 0.31%	3,458,830 $96.3 Million
Q4 2020 Feb 16, 2021	BUY	$20.81 - $30.55 $122,945 - $180,489	5,908 Added 0.17%	3,448,030 $86.3 Million
Q3 2020 Nov 16, 2020	BUY	$17.5 - $30.23 $60.2 Million - $104 Million	3,442,122 New	3,442,122 $104 Million

Others Institutions Holding ANNX

# of Institutions

156

Shares Held

101M

Call Options Held

3.73M

Put Options Held

1.3M

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $274M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Annexon, Inc. Transaction History